Interleukin-1 beta inhibitor canakinumab added to concurrent chemoradiotherapy and consolidative durvalumab produced favorable progression-free survival results in the phase I/II CHORUS trial for unresectable stage III non-small cell lung cancer. The study reported a 24-month progression-free survival rate of 67%, positioning the IL-1 pathway as an escalation lever in a setting dominated by durvalumab. The trial design combines chemo-radiation with immune checkpoint consolidation while testing an anti-inflammatory target to potentially reduce treatment resistance. The outcomes are early-phase, but the magnitude of the reported PFS supports further evaluation of IL-1 targeting in combination regimens. For oncology developers, CHORUS adds to the growing emphasis on stacking immunotherapy with pathway-directed agents in locally advanced disease.